Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lara S Kallander

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The Journal of Organic Chemistry|October 25, 2001
A Versatile Enantioselective Strategy Toward L-C-Nucleosides: A Total Synthesis of L-ShowdomycinBarry M. Trost, Lara S. Kallander
Journal of Medicinal Chemistry|December 10, 2016
Substituent Effects on Drug-Receptor H-bond Interactions: Correlations Useful for the Design of Kinase InhibitorsBrian G Lawhorn, Joanne Philp, Alan P Graves, et al.
Bioorganic & Medicinal Chemistry Letters|June 2, 2016
GSK114: A selective inhibitor for elucidating the biological role of TNNI3KBrian G Lawhorn, Joanne Philp, Alan P Graves, et al.
Journal of Medicinal Chemistry|March 22, 2018
4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) InhibitorsJoanne Philp, Brian G Lawhorn, Alan P Graves, et al.
Journal of Medicinal Chemistry|October 26, 2021
Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-RafJaclyn R Patterson, Alan P Graves, Patrick Stoy, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2005
Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonistsDavid G Jones, Xi Liang, Eugene L Stewart, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2009
The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophagesJoseph P Marino, Lara S Kallander, Chun Ma, et al.
Science Translational Medicine|October 18, 2013
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heartRonald J Vagnozzi, Gregory J Gatto, Lara S Kallander, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2017
Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibitionBrian G Lawhorn, Tritin Tran, Victor S Hong, et al.
Journal of Medicinal Chemistry|September 11, 2015
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K)Brian G Lawhorn, Joanne Philp, Yongdong Zhao, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Journal of Organic Chemistry|October 25, 2001
A Versatile Enantioselective Strategy Toward L-C-Nucleosides: A Total Synthesis of L-ShowdomycinBarry M. Trost, Lara S. Kallander
Journal of Medicinal Chemistry|December 10, 2016
Substituent Effects on Drug-Receptor H-bond Interactions: Correlations Useful for the Design of Kinase InhibitorsBrian G Lawhorn, Joanne Philp, Alan P Graves, et al.
Bioorganic & Medicinal Chemistry Letters|June 2, 2016
GSK114: A selective inhibitor for elucidating the biological role of TNNI3KBrian G Lawhorn, Joanne Philp, Alan P Graves, et al.
Journal of Medicinal Chemistry|March 22, 2018
4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) InhibitorsJoanne Philp, Brian G Lawhorn, Alan P Graves, et al.
Journal of Medicinal Chemistry|October 26, 2021
Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-RafJaclyn R Patterson, Alan P Graves, Patrick Stoy, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2005
Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonistsDavid G Jones, Xi Liang, Eugene L Stewart, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2009
The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophagesJoseph P Marino, Lara S Kallander, Chun Ma, et al.
Science Translational Medicine|October 18, 2013
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heartRonald J Vagnozzi, Gregory J Gatto, Lara S Kallander, et al.
Bioorganic & Medicinal Chemistry Letters|October 8, 2017
Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibitionBrian G Lawhorn, Tritin Tran, Victor S Hong, et al.
Journal of Medicinal Chemistry|September 11, 2015
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K)Brian G Lawhorn, Joanne Philp, Yongdong Zhao, et al.
Pageof 2